takisbiotech
Menu
Close
Company
About Us
Our Team
Careers
Our Services
Vaccines & Preclinical Immunology
Predictive Models
Monoclonal Antibodies
Recombinant Proteins
Facilities
BSL-3
GMP
Research
Funded Projects
Internal Research
Papers
Congresses
News
Contact Us
Company
About Us
Our Team
Careers
Our Services
Vaccines & Preclinical Immunology
Predictive Models
Monoclonal Antibodies
Recombinant Proteins
Facilities
BSL-3
GMP
Research
Funded Projects
Internal Research
Papers
Congresses
News
Contact Us
Company news
Stay updated with Takis latest news!
Vitares in the Spera Federation
January 25, 2024
|
News
|
National Center for mRNA and Gene Therapies
January 22, 2024
|
News
|
Takis was among the winners of the Open Infrastructures for Research 2022 tender by Lazio Innova
January 16, 2024
|
News
|
Isolation and Characterization of Neutralizing Monoclonal Antibodies Against RBD of the SARS-CoV-2 Spike Protein
January 10, 2024
|
News
|
Takis biotech is at the forefront of the development of solutions against pathogens with high epidemic/pandemic potential.
May 7, 2023
|
News
|
COVID-eVax PHASE 1 CLINICAL TRIAL RESULTS PUBLISHED
January 7, 2023
|
News
|
Takis is glad to announce the promotion of Giuseppe Roscilli and Emanuele Marra in their new roles.
January 1, 2023
|
News
|
BIO International Convention
June 7, 2022
|
News
|
1
2
3
4
